Carlsbad’s Ionis gets $25M upfront for licensing hepatitis B drugs to GSK

Carlsbad's Ionis gets $25M upfront for licensing hepatitis B drugs to GSK
/

Hundreds of millions more possible to Ionis if drugs reach milestones